ProImmune Ltd., a leader in services for understanding immune responses, has launched the B cell ELISpot assay as a service. The B cell ELISpot assay is central to the characterization of adaptive immune responses to infection, immune modulators, vaccines and therapeutic agents.
Used to quantify the number of memory B cells that can be re-stimulated to produce antibody against a specific antigen, B cell ELISpot enables the activity of antibody-secreting memory B cells to be characterized at a cellular level. This gives a more detailed reading of immune responses in contrast to an ELISA-type assay, which measures total levels of secreted antibodies in a sample.
Dr. Nikolai Schwabe, CEO of ProImmune said: “The B cell ELISpot is a highly valuable assay offering a superior method for characterization of memory antibody responses, the investigation of which forms a mainstay of evaluating functional immune responses.”
Date: April 19, 2012
Source: ProImmune Ltd.